Maraviroc: a new CCR5 antagonist (Q37557671)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on February 2009

Language	Label	Description	Also known as
English	Maraviroc: a new CCR5 antagonist	scientific article published on February 2009

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

1 reference

Europe PubMed Central

Maraviroc: a new CCR5 antagonist (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

0 references

author name string

Shilpa Sayana

1

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Homayoon Khanlou

2

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

publication date

1 February 2009

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Expert Review of Anti-infective Therapy

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

9-19

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Co-receptor antagonists as HIV-1 entry inhibitors.

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

Biology of CCR5 and its role in HIV infection and treatment

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

Chemokine antagonists as therapeutics: focus on HIV-1.

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

CCR5 inhibitors: promising yet challenging

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele.

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1.

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

HIV entry inhibitors.

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

CCR5 deficiency increases risk of symptomatic West Nile virus infection

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

1 reference

https://api.crossref.org/works/10.1586%2F14787210.7.1.9

21 January 2018

Identifiers

10.1586/14787210.7.1.9

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37557671&oldid=2166466076"